NTEC实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jan 1970 @ 08:00):

Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel...

Stats
今日成交量	988 303
平均成交量	1.05M
市值	0.00
EPS	$0 ( 2021-08-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.345 (3.58%)

Insider Trading

Date	Person	Action	Amount	type
2021-07-23	Hayes William B	Sell	250	Stock Option (right to buy)
2021-07-23	Hayes William B	Sell	250	Stock Option (right to buy)
2021-07-23	Hayes William B	Sell	500	Stock Option (right to buy)
2021-07-23	Karah Hila	Sell	281	Stock Option (right to buy)
2021-07-23	Karah Hila	Sell	250	Stock Option (right to buy)

INSIDER POWER
0.00
Last 59 transactions
Buy: 3 599 185 \| Sell: 7 817 315

音量相关性

長: 0.44 (neutral)

短: 0.85 (strong)

Signal:(64.456) Same movement expected

Intec Pharma Ltd 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Intec Pharma Ltd 相关性 - 货币/商品

0.42
( neutral )

0.46
( neutral )

-0.20
( neutral )

0.28
( neutral )

-0.36
( neutral )

-0.32
( neutral )

Intec Pharma Ltd 财务报表

Annual	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-14.30

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-14.30

FY	2019
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-112.74

FY	2018
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-111.67

Financial Reports:

No articles found.

Intec Pharma Ltd

Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.